.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a typical follow-up of 11 months, people with metastatic gastrointestinal cysts that received biomarker-matched therapies based upon spreading tumor DNA profiling revealed a greater medical benefit than those receiving unparalleled therapy.